Cargando…

cDCBLD2 mediates sorafenib resistance in hepatocellular carcinoma by sponging miR-345-5p binding to the TOP2A coding sequence

Sorafenib is a first-line chemotherapy drug for treating advanced hepatocellular carcinoma (HCC). However, its therapeutic effect has been seriously affected by the emergence of sorafenib resistance in HCC patients. The underlying mechanism of sorafenib resistance is unclear. Here, we report a circu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruan, YeLing, Chen, TianYi, Zheng, LongBo, Cai, JingWei, Zhao, Hu, Wang, YaLi, Tao, LiYe, Xu, JunJie, Ji, Lin, Cai, XiuJun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535695/ https://www.ncbi.nlm.nih.gov/pubmed/37781045 http://dx.doi.org/10.7150/ijbs.86227

Ejemplares similares

Bulk and single-cell transcriptome profiling reveal extracellular matrix mechanical regulation of lipid metabolism reprograming through YAP/TEAD4/ACADL axis in hepatocellular carcinoma
por: Cai, Jingwei, et al.
Publicado: (2023)

UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma
por: Xu, Junjie, et al.
Publicado: (2021)

Dynamic multi-site phosphorylation by Fyn and Abl drives the interaction between CRKL and the novel scaffolding receptors DCBLD1 and DCBLD2
por: Schmoker, Anna M., et al.
Publicado: (2017)

Pan-cancer analyses identify DCBLD2 as an oncogenic, immunological, and prognostic biomarker
por: Xie, Pan, et al.
Publicado: (2022)

Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals
por: Xu, Junjie, et al.
Publicado: (2017)

TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance
por: Xia, Shunjie, et al.
Publicado: (2021)

Circ-RAPGEF5 promotes intrahepatic cholangiocarcinoma progression by stabilizing SAE1 to facilitate SUMOylation
por: Zheng, Junhao, et al.
Publicado: (2023)

The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma
por: Xia, Shunjie, et al.
Publicado: (2020)

DCBLD2 Mediates Epithelial-Mesenchymal Transition-Induced Metastasis by Cisplatin in Lung Adenocarcinoma
por: Chen, Xiaosu, et al.
Publicado: (2021)

FYN and ABL Regulate the Interaction Networks of the DCBLD Receptor Family
por: Schmoker, Anna M., et al.
Publicado: (2020)

Transcriptomic Profiling Identifies DCBLD2 as a Diagnostic and Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma
por: Feng, Zengyu, et al.
Publicado: (2021)

LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription
por: Lin, Zhongjie, et al.
Publicado: (2020)

Potential Association of DCBLD2 Polymorphisms with Fall Rates of FEV(1) by Aspirin Provocation in Korean Asthmatics
por: Park, Tae-Joon, et al.
Publicado: (2012)

DCBLD2 Affects the Development of Colorectal Cancer via EMT and Angiogenesis and Modulates 5-FU Drug Resistance
por: Xie, Pan, et al.
Publicado: (2021)

Sorafenib with ASC‐J9(®) synergistically suppresses the HCC progression via altering the pSTAT3‐CCL2/Bcl2 signals
por: Xu, Junjie, et al.
Publicado: (2016)

A homozygous nonsense mutation in DCBLD2 is a candidate cause of developmental delay, dysmorphic features and restrictive cardiomyopathy
por: Alhamoudi, Kheloud M., et al.
Publicado: (2021)

Long non-coding RNA LINC01426 facilitates glioblastoma progression via sponging miR-345-3p and upregulation of VAMP8
por: Cao, Jingwei, et al.
Publicado: (2020)

DCBLD1 Overexpression Is Associated With a Poor Prognosis in Head and Neck Squamous Cell Carcinoma
por: Fu, Ling-ling, et al.
Publicado: (2022)

miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR
por: Ji, Lin, et al.
Publicado: (2020)

CD146 promotes malignant progression of breast phyllodes tumor through suppressing DCBLD2 degradation and activating the AKT pathway
por: Chen, Jiewen, et al.
Publicado: (2023)

Corrigendum: DCBLD1 Overexpression is associated with a poor prognosis in head and neck squamous cell carcinoma
por: Fu, Ling-ling, et al.
Publicado: (2022)

Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma
por: Liang, Yuelong, et al.
Publicado: (2017)

Suppression of circDcbld1 Alleviates Intimal Hyperplasia in Rat Carotid Artery by Targeting miR-145-3p/Neuropilin-1
por: Rong, Zhi-Hua, et al.
Publicado: (2019)

Engineering siRNA-loaded and RGDfC-targeted selenium nanoparticles for highly efficient silencing of DCBLD2 gene for colorectal cancer treatment
por: Huang, Hongli, et al.
Publicado: (2023)

The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals
por: Xu, Junjie, et al.
Publicado: (2016)

CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1
por: Xu, Junjie, et al.
Publicado: (2020)

DCBLD1 is associated with the integrin signaling pathway and has prognostic value in non-small cell lung and invasive breast carcinoma
por: Cardin, Guillaume B., et al.
Publicado: (2021)

CircUBAP2 Promotes MMP9-Mediated Oncogenic Effect via Sponging miR-194-3p in Hepatocellular Carcinoma
por: Liu, Boqiang, et al.
Publicado: (2021)

LINC00885 promotes cervical cancer progression through sponging miR-3150b-3p and upregulating BAZ2A
por: Liu, Yeling, et al.
Publicado: (2022)

SNP rs17079281 decreases lung cancer risk through creating an YY1-binding site to suppress DCBLD1 expression
por: Wang, Yu, et al.
Publicado: (2020)

SNP rs9387478 at ROS1-DCBLD1 Locus is Significantly Associated with Lung Cancer Risk and Poor Survival in Indian Population
por: Chongtham, Jonita, et al.
Publicado: (2022)

N(6)-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling
por: Xu, Junjie, et al.
Publicado: (2020)

Preclinical Toxicology of rQNestin34.5v.2: An Oncolytic Herpes Virus with Transcriptional Regulation of the ICP34.5 Neurovirulence Gene
por: Chiocca, E. Antonio, et al.
Publicado: (2020)

Long noncoding RNA SNHG16 induces sorafenib resistance in hepatocellular carcinoma cells through sponging miR-140-5p
por: Ye, Junfeng, et al.
Publicado: (2019)

Introduction of Mercaptoethyl at Sorafenib Pyridine-2-Amide Motif as a Potentially Effective Chain to Further get Sorafenib-PEG-DGL
por: Wang, Ke, et al.
Publicado: (2020)

345 The Role of TCF7L2 in Hepatic Metabolic Zonation
por: Ayala, Iriscilla I., et al.
Publicado: (2023)

NSK-01105, a Novel Sorafenib Derivative, Inhibits Human Prostate Tumor Growth via Suppression of VEGFR2/EGFR-Mediated Angiogenesis
por: Yu, Pengfei, et al.
Publicado: (2014)

Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors
por: Fu, Yali, et al.
Publicado: (2018)

Arginase 2 negatively regulates sorafenib-induced cell death by mediating ferroptosis in melanoma: The role of Arginase 2 in sorafenib-induced ferroptosis in melanoma
por: Yu, Yi, et al.
Publicado: (2022)

ELF3 promotes epithelial–mesenchymal transition by protecting ZEB1 from miR-141-3p-mediated silencing in hepatocellular carcinoma
por: Zheng, Longbo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pgmghe31tposalhemg6a5s98s1